1st Annual European BioPharma Obesity Innovation Forum

The current obesity pandemic is arguably the greatest challenge to 21st-century global health. The pharmaceutical market is estimated to exceed $100 billion by 2030, notwithstanding the pressure on payers. More positively, we are also learning more and more about the broad health benefits of GLP-1 medicines beyond even cardio-metabolic diseases.

The conference will highlight cutting-edge academic research, explore the European obesity landscape, and showcase the latest advances in drug development, treatment approaches, and investment opportunities. Delegates will gain a comprehensive understanding of Europe’s market and its role in shaping global innovation.